Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bayer AG | 592 |
| 2 | BASF SE | 354 |
| 3 | Sinochem Holdings Corp Ltd | 149 |
| 4 | Corteva Inc | 123 |
| 5 | Merck and Co Inc | 104 |
| 6 | Sumitomo Chemical Co Ltd | 104 |
| 7 | Elanco Animal Health Inc | 92 |
| 8 | C.H. Boehringer Sohn AG and Co KG | 57 |
| 9 | Zoetis Inc | 41 |
| 10 | Nippon Soda Co Ltd | 40 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A01N | Preservation of bodies; biocides; pest repellents | 2,065 |
| 2 | C07D | Heterocyclic compounds | 1,617 |
| 3 | A01P | Biocidal activity of chemical compounds | 1,023 |
| 4 | A61P | Therapeutic activity (drug indications) | 766 |
| 5 | A61K | Medicinal preparations | 571 |
| 6 | C07C | Acyclic and carbocyclic compounds | 253 |
| 7 | Y02A | Climate change adaptation | 229 |
| 8 | A01C | 109 | |
| 9 | C07F | Organometallic compounds | 103 |
| 10 | C05G | 91 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Methods for treating demodex blepharitis using lotilaner formulations | 2023 | Tarsus Pharmaceuticals Inc | 3 |
| Methods for treating ocular Demodex using lotilaner formulations | 2023 | Tarsus Pharmaceuticals Inc | 3 |
| Ophthalmic compositions for treating ocular Demodex using lotilaner formulations | 2023 | Tarsus Pharmaceuticals Inc | 1 |
| PROCESS FOR LOTILANER INTERMEDIATE | 2022 | Elanco Animal Health Inc | 0 |
| Lotilaner and salts thereof | 2017 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2020 | 2 |
| 2021 | 14 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 6 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Scott Wiseman | Elanco (United States) | 11 |
| 2 | Daniel E. Snyder | Danieli (Italy) | 6 |
| 3 | Lisa Young | Elanco (United States) | 5 |
| 4 | Elizabeth Yeu | Virginia Eye Consultants | 5 |
| 5 | Mark Holdbrook | Taro Pharmaceuticals (United States) | 5 |
| 6 | Stephanie N. Baba | Taro Pharmaceuticals (United States) | 5 |
| 7 | Craig R. Reinemeyer | East Tennessee Clinical Research | 4 |
| 8 | Kari L. Riggs | Elanco (United States) | 3 |
| 9 | Martha Massaro-Corredor | Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes | 3 |
| 10 | Juan Carlos Ceballos | Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1) | 2022 | 51 | Ocular Surface and Contact Lens |
| Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis | 2023 | 47 | Ocular Surface and Contact Lens |
| Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial | 2021 | 32 | Olfactory and Sensory Function Studies |
| A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™ CAT) in eliminating fleas in client-owned cats in the USA | 2021 | 29 | Dermatology and Skin Diseases |
| Lotilaner Ophthalmic Solution 0.25%: First Approval | 2023 | 20 | Acne and Rosacea Treatments and Effects |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Lotilaner?
Which companies hold the most patents related to Lotilaner?
What are the main medical applications of Lotilaner based on recent patents and publications?
How has patent activity for Lotilaner evolved over time?
What are the primary patent classification areas for Lotilaner?